Massachusetts Chapter of the American College of Surgeons

MCACS Home MCACS Home Past & Future Meetings Past & Future Meetings

Back to 2026 Display Posters


Urgency and Equity: Analytic Study of Site Context Representation in US Emergency (EFIC) Clinical Trials
Sai Sankeerth Madakasira, MD, MS,1 Anne Kathleen. Buck, MS, PHD 1,2 Janice Weinberg, ScD 1,2 Susan S. Fish, PharmD, MPH 1. 1 Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 2 Boston University School of Public Health, Boston, MA

Background: Scarce information exists on factors impacting enrolment in emergency clinical trials with exception from informed consent (EFIC trials) in the US. Consistent underrepresentation of minorities in traditional clinical trials has been contradicted by sparse evidence of minority over representation in EFIC trials, which are largely spearheaded by trauma, emergency, acute-care specialists. We hypothesized that minority overrepresentation is related to hospital context where EFIC trials occur. Methods: Retrospective analytic study of EFIC trials completed in US between 1996 and 2025 using FDA docket-1995-S-0036 was performed. Abstracted trial-level enrollment was used to calculate representation ratio (RR), representation difference (RD) and minority enrollment proportions (MEP), using CDC/ATSDR, NCHS urban-rural classification schemes and US census data. Results: Trial-level, population weighted representation metrics (RR, RD, MEP) of 17 EFIC trials showed 209 [IQR, 100-882] median participants per trial, 4 [IQR 1-11] median sites per trial. EFIC trials were predominantly conducted in counties with moderate to high social vulnerability Index (SVI) with median population-weighted SVI of 0.68 [IQR 0.33-0.78]. Each 0.1 increase in SVI was associated with a 5-6 percentage-point increase in the MEP (β=0.56, SE=0.26, p=0.0515), indicating a positive association between SVI and minority representation. Conclusion: EFIC trials are largely clustered in urban centers catering socially vulnerable counties and enroll higher minority participants. Alongside engagement of high-burden communities, our study also highlights potential concentration of research burden. These results heighten the importance of using SVI, race/ethnicity distributions prospectively at site selection, trial design and monitoring stages to account for generalizability and ethical considerations.

Back to 2026 Display Posters